1.Expert consensus on dispensing management of intravenous infusion drugs for clinical trials in PIVAS
Xingchen YANG ; Wenhuan FU ; Donghui LAO ; Jing ZHAO ; Jianzhong ZHANG ; Group PHARMACY ; Committee HOSPITAL ; Association Pharmaceutical SHANGHAI
China Pharmacy 2025;36(1):1-6
OBJECTIVE To further standardize the dispensing management standard of intravenous infusion drugs for clinical trials in pharmacy intravenous admixture services (PIVAS), and provide reference for medical institutions to provide high-quality pharmaceutical services. METHODS Initiated by PIVAS Group, Hospital Pharmacy Professional Committee, Shanghai Pharmaceutical Association, jointly led by Longhua Hospital, Shanghai University of Traditional Chinese Medicine and Shanghai Geriatric Medical Center, a writing group was established by PIVAS experts from multiple medical institutions to discuss the basic requirements and dispensing process of intravenous infusion drugs for clinical trials in PIVAS. The experts from the leading unit sorted out, summarized, analyzed, fed back and revised the opinions, and finally reached Expert Consensus on Dispensing Management of Intravenous Infusion Drugs for Clinical Trials in PIVAS. RESULTS & CONCLUSIONS The main contents of this consensus include information management, operation process, fund management and document management of intravenous infusion drugs for clinical trials in PIVAS. This consensus establishes a more standardized model for dispensing management of intravenous infusion drugs for clinical trials in PIVAS, by standardizing clinical trail drug management operational procedures, accurately recording and preserving drug-related information, with the aim of achieving standardized and meticulous management of PIVAS’s receipt of clinical trial drugs.
2.Expert opinions on operation rules of Morita therapy outpatient service
Jiangbo LI ; Zucheng WANG ; Yuhua CUI ; Yingzhi LU ; Weijie QU ; Haiyin ZHANG ; Fuqiang MAO ; Fengqing QIE ; Wanghong SHI ; Qinfeng ZHANG ; Lingyi PAN ; Ling ZHANG ; Jianzhong LI ; Guangcheng CUI ; Tongxian CHEN ; Xiuqing MA ; Wei RONG ; Jianjun ZHANG ; Qingfang ZHONG ; Yanchi ZHANG ; Boquan ZHANG ; Xinrui WANG ; Wenyou MA ; Qingtao REN ; Yongfa JING ; Huanzhong LIU ; Zhenjian YU ; Laitian ZHAO ; Tianming HAN ; Xue HAN
Chinese Mental Health Journal 2024;38(1):68-72
Morita therapy has been bom for more than 100 years.Inpatient Morita therapy is highly oper-able and easy to master.It can improve many refractory neuroses through four-stage treatment.But more neuroses are treated in outpatient clinics,and Morita therapy cannot be used in hospitalized patients.Therefore,the formula-tion of expert opinions on outpatient operations is particularly important.This paper is based on domestic and for-eign references,and after many discussions by domestic Morita therapy experts,and then drew up the first version of the expert opinions on operation of outpatient Morita therapy.Meanwhile the operation rule of Morita therapy in three stages of outpatient treatment was formulated:in the etiological analysis stage,under the theoretical guidance of Morita therapy,analyze the pathogenic factors,to improve treatment compliance and reduce resistance;during the operating stage,guide patients to engage in constructive and meaningful actions,realizing the achievement of letting nature take its course principle;in the cultivating character and enriching life stage,pay attention to positive infor-mation,expanding the scope and content of actions,improving the ability to adapt to complex life,and preventing recurrence caused by insufficient abilities.It will lay a foundation for the promotion of Morita therapy in domestic outpatient clinics,so that more patients with neurosis and other psychological diseases could receive characteristic Morita therapy treatment in outpatient clinics.
3.Research and analysis of the blending types and workload of PIVAS in China
Hongmei LYU ; Jing ZHAO ; Yuqi FU ; Jianzhong ZHANG
China Pharmacy 2024;35(18):2203-2206
OBJECTIVE To assess the blending types and workload of pharmacy intravenous admixture services (PIVAS) in China. METHODS By questionnaire survey, the working status of PIVAS in different levels of hospitals nationwide was investigated, involving the types of blending infusion, daily blending volume of hazardous drugs infusion, parenteral nutrition solution, general and antibacterial drug infusion, intravenous bolus drugs, skin test solution and intravenous agents, as well as the daily packing volume. RESULTS A sample of 750 PIVAS in 30 provinces (autonomous regions, municipalities) across China were surveyed by questionnaire, involving 621 tertiary hospitals and 90 secondary hospitals. The main types of liquid preparation were intravenous infusion, followed by parenteral nutrition solution, and chemotherapy pump (including chemotherapy infusion), accounting for 99.73%, 79.47% and 43.33%, respectively. The daily blending volume of hazardous drugs infusion, parenteral nutrition solution, general and antibacterial drug infusion, intravenous bolus drugs, skin test solution and intravenous agents in PIVAS of tertiary hospitals were 23.00 (9.00, 56.50) sets, 31.00 (13.97, 74.00) bags, 813.00 (375.00, 2 061.75) bags, 426.00 (210.00, 987.00) bags, 30.00 (6.00, 155.00) ampoules, 30.00 (7.13, 136.84) ampoules, 3 200.00 (1 684.50, 5 554.50) ampoules respectively, while the daily packing volume was 218.50 (52.26, 559.00) bags; above indexes of PIVAS in secondary hospital were 4.00(2.00,12.00)sets, 8.90(3.00,23.00)bags, 270.50(108.00, 2 061.75)bags, 157.00(71.00,987.00)bags, 5.85 (3.75,141.00) ampoules, 0 ampoule, 1 349.00(548.10,2 408.00)ampoules, 107.50(33.25,207.00)bags. CONCLUSIONS The scope of blending types of PIVAS has been significantly expanded, and tertiary hospitals are significantly higher than secondary hospitals in the blending and packing volumes of all types of intravenous fluids and drugs dispensed, showing obvious advantages in dealing with complex medications and high-risk treatments.
4.Investigation and analysis of the medical prescription approval in PIVAS in China
Jing ZHAO ; Lulu SUN ; Hongmei LYU ; Jianzhong ZHANG
China Pharmacy 2024;35(19):2340-2344
OBJECTIVE To know about the current status of medical order auditing in pharmacy intravenous admixture service (PIVAS) of medical institutions nationwide, further improve the management of medical orders in PIVAS, and reduce and eliminate the occurrence of intravenous medication administration errors. METHODS Through the questionnaire survey method, to address the problems and current situation of PIVAS medical order auditing in medical institutions nationwide, experts from each province (autonomous region, municipality directly under the central government) in the research group were responsible for organizing the PIVAS directors of relevant medical institutions in their provinces to fill in the questionnaires on medical order audit and inappropriate medical order interventions, and conduct a statistical analysis of the results. RESULTS A total of valid 751 responses were received to the PIVAS questionnaire on the review of medical prescriptions. Our PIVAS medical order audit is mainly carried out by a combination of manual and computer. The median number of medical orders were audited by PIVAS per day were 700.00-771.00; the median number of new medical orders were audited by PIVAS per day were 209.68-215.00; medical order auditing rates were 85.50%-92.44% averagely; the inappropriate doctor’s orders accounted for 1.82%-1.89% averagely; the intervention rates of inappropriate medical orders ranged 74.90%-79.41%, the success rates of intervention were 79.62%-87.28% averagely; the medication refund rates were 2.92%-3.08%. CONCLUSIONS Most of the PIVAS in China’s healthcare institutions use medical order review software to assist in the review of medical orders, and there are cases of individual PIVAS in which medical orders are not reviewed comprehensively and inappropriate orders are not intervened in, and the standards and processes of medical prescription review need to be improved. It is recommended to emphasize the pharmacist’s responsibility system, standardize the use of prescription review software; gradually expand the scope of medical order review, and adopt a multi-departmental collaborative approach so as to increase the success rate of intervention for inappropriate prescriptions and reduce the rate of PIVAS withdrawals.
5.Construction of a diagnostic model based on random forest and artificial neural network for peri-implantitis
Haoran YANG ; Yuxiang CHEN ; Anna ZHAO ; Tingting CHENG ; Jianzhong ZHOU ; Ziliang LI
West China Journal of Stomatology 2024;42(2):214-226
Objective This study aimed to reveal critical genes regulating peri-implantitis during its development and construct a diagnostic model by using random forest(RF)and artificial neural network(ANN).Methods GSE-33774,GSE106090,and GSE57631 datasets were obtained from the GEO database.The GSE33774 and GSE106090 da-tasets were analyzed for differential expression and functional enrichment.The protein-protein interaction networks(PPI)and RF screened vital genes.A diagnostic model for peri-implantitis was established using ANN and validated on the GSE33774 and GSE57631 datasets.A transcription factor-gene interaction network and a transcription factor-micro-RNA(miRNA)regulatory network were also established.Results A total of 124 differentially expressed genes(DEGs)involved in the regulation of peri-implantitis were screened.Enrichment analysis showed that DEGs were mainly associated with immune receptor activity and cytokine receptor activity and were mainly involved in processes such as leukocyte and neutrophil migration.The PPI and RF screened six essential genes,namely,CD38,CYBB,FCGR2A,SELL,TLR4,and CXCL8.The receiver oper-ating characteristic curve(ROC)indicated that the ANN model had an excellent diagnostic performance.FOXC1,GA-TA2,and NF-κB1 may be essential transcription factors in peri-implantitis,and hsa-miR-204 may be a key miRNA.Con-clusion The diagnostic model of peri-implantitis constructed by RF and ANN has high confidence,and CD38,CYBB,FCGR2A,SELL,TLR4,and CXCL8 are potential diagnostic markers.FOXC1,GATA2,and NF-κB1 may be essential transcription factors in peri-implantitis,and hsa-miR-204 plays a vital role as a critical miRNA.
6.The role and its regulatory significance of interleukin-25 in ovalbumin induced atopic dermatitis of mice
Jiang JIN ; Xue CHEN ; Yan ZHAO ; Jun JIA ; Jianzhong ZHANG
Journal of Peking University(Health Sciences) 2024;56(5):756-762
Objective:To investigate the effect of interleukin-25(IL-25)on ovalbumin(OVA)in-duced atopic dermatitis of mice,and the significance of regulating IL-25.Methods:In this study,90 healthy male 6-week-old specific pathogen free(SPF)BALB/c mice were divided into 6 groups(15 in each group):① subcutaneous injection of phosphate buffered saline(PBS)group(normal control group);② subcutaneous injection of mouse IL-25 group(IL-25 group);③ subcutaneous injection of anti-mouse IL-25 monoclonal antibody(anti-IL-25 group),each group received subcutaneous injection once a day for 1 week,2 weeks apart,repeated daily subcutaneous injections for 1 week,2 weeks apart,and repeated daily subcutaneous injections for 1 week,for a total of 7 weeks;④OVA treated group(model group);⑤ OVA treated and IL-25 subcutaneous injection group(IL-25 treated dermatitis group);⑥ OVA treated and anti-mouse IL-25 monoclonal antibody injection group(anti-IL-25 treated dermatitis group).The ⑤ and ⑥ groups in the process of treatment with OVA,IL-25 or anti-IL-25 anti-body were given in the same way as the ② and ③ groups.Scratching behavior and skin performance of the mice were recorded during the seven-week-treatment.Twenty four hours after the final treatment,blood was taken from the mouse heart,and the serum was separated to detect the total IgE,IL-4,IL-5,IL-13,etc.The skin samples of the treatment sites were used for hematoxylin-eosin(HE)staining,im-munohistochemistry,real-time PCR and Western blot detections.A single factor(ANOVA)analysis of variance was used to compare the differences in various indicators between the groups.Results:The fre-quency of scratches in the IL-25 treated dermatitis group was higher than that in the model group,and the scratching behavior of the anti-IL-25 treated dermatitis group was significantly lower than that in the model group.The appearance of atopic dermatitis,thickening of the epidermis and the degree of dermal inflammation in the IL-25 treated dermatitis group were more serious than those in the model group and the anti-IL-25 treated dermatitis group.The levels of serum IgE,IL-4,IL-5,and IL-13 in the IL-25 treated dermatitis group were significantly higher than that in the model group and the anti-IL-25 treated dermatitis group.There were significantly more CD4+T cells in the dermis of IL-25 treated dermatitis group than that in the anti-IL-25 treated dermatitis group.The expression levels of filaggrin and defensinβ2 proteins in the IL-25 treated dermatitis group were significantly lower than those in the model group and the anti-IL-25 treated dermatitis group.Conclusion:In the OVA induced atopic dermatitis mice model,IL-25 can significantly promote the damage of the epidermal barrier function and aggravate the OVA-induced dermatitis.Antagonizing IL-25 can alleviate OVA induced dermatitis to a certain extent.
7.Application of electrochemical sensors based on graphene nanomaterials in the infectious diseases detection
Ying YE ; Jianzhong YE ; Ran ZHANG ; Li ZHU ; Jian'an HE ; Chunzhong ZHAO ; Caijun SUN
International Journal of Laboratory Medicine 2024;45(12):1511-1515
Graphene,as a new type of two-dimensional nanomaterial,has unique physical and chemical properties,which make it characterized by low resistivity,large specific surface area,good biocompatibility,and high chemical stability.It is expected to develop into an ideal material for highly sensitive electrochemical sensors.With the development of electrochemical sensor technology,graphene based electrochemical sensors with high sensitivity,specificity,speed,and convenience can be used to detect various infectious disease patho-gens.This article summarizes the application of electrochemical sensor detection technology based on graphene nanomaterials in the detection of respiratory pathogens,mosquito borne infectious disease pathogens,intestinal infectious disease pathogens,and other infectious disease pathogens,providing new ideas for achieving rapid detection technology and methods for early detection and diagnosis of infectious diseases.
8.Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
Yan ZHAO ; Jianzhong ZHANG ; Bin YANG ; Jingyi LI ; Yangfeng DING ; Liming WU ; Litao ZHANG ; Jinyan WANG ; Xiaohong ZHU ; Furen ZHANG ; Xiaohua TAO ; Yumei LI ; Chunlei ZHANG ; Linfeng LI ; Jianyun LU ; Qingchun DIAO ; Qianjin LU ; Xiaoyong MAN ; Fuqiu LI ; Xiujuan XIA ; Hao CHENG ; Yingmin JIA ; Guoqing ZHAO ; Jinchun YAN ; Bo CHEN
Chinese Medical Journal 2024;137(2):200-208
Background::Atopic dermatitis (AD) affects approximately 10% of adults worldwide. CM310 is a humanized monoclonal antibody targeting interleukin-4 receptor alpha that blocks interleukin-4 and interleukin-13 signaling. This trial aimed to evaluate the efficacy and safety of CM310 in Chinese adults with moderate-to-severe AD.Methods::This multicenter, randomized, double-blind, placebo-controlled, phase 2b trial was conducted in 21 medical institutions in China from February to November 2021. Totally 120 eligible patients were enrolled and randomized (1:1:1) to receive subcutaneous injections of 300 mg CM310, 150 mg CM310, or placebo every 2 weeks for 16 weeks, followed by an 8-week follow-up period. The primary endpoint was the proportion of patients achieving ≥75% improvement in the Eczema Area and Severity Index (EASI-75) score from baseline at week 16. Safety and pharmacodynamics were also studied.Results::At week 16, the proportion of EASI-75 responders from baseline was significantly higher in the CM310 groups (70% [28/40] for high-dose and 65% [26/40] for low-dose) than that in the placebo group (20%[8/40]). The differences in EASI-75 response rate were 50% (high vs. placebo, 95% CI 31%–69%) and 45% (low vs. placebo, 95% CI 26%–64%), with both P values <0.0001. CM310 at both doses also significantly improved the EASI score, Investigator’s Global Assessment score, daily peak pruritus Numerical Rating Scale, AD-affected body surface area, and Dermatology Life Quality Index compared with placebo. CM310 treatment reduced levels of thymus and activation-regulated chemokine, total immunoglobulin E, lactate dehydrogenase, and blood eosinophils. The incidence of treatment-emergent adverse events (TEAEs) was similar among all three groups, with the most common TEAEs reported being upper respiratory tract infection, atopic dermatitis, hyperlipidemia, and hyperuricemia. No severe adverse events were deemed to be attributed to CM310. Conclusion::CM310 at 150 mg and 300 mg every 2 weeks demonstrated significant efficacy and was well-tolerated in adults with moderate-to-severe AD.Trial Registration::ClinicalTrials.gov, NCT04805411.
9.A multi-center, double-blind, randomized, placebo- and positive-controlled phase II clinical study of benvitimod for the treatment of atopic dermatitis.
Lin CAI ; Yan ZHAO ; Min ZHENG ; Furen ZHANG ; Qing SUN ; Quanzhong LIU ; Jin HU ; Juan SHEN ; Jianzhong ZHANG
Chinese Medical Journal 2023;136(2):251-252
10.Application and research progress of artificial intelligence technology in trauma treatment.
Heng ZHANG ; Xiaodong MA ; Jiaqin WANG ; Jianzhong GUAN ; Kuanxin LI ; Jianning ZHAO ; Jiansheng ZHOU
Chinese Journal of Reparative and Reconstructive Surgery 2023;37(11):1431-1437
OBJECTIVE:
To review the application and research progress of artificial intelligence (AI) technology in trauma treatment.
METHODS:
The recent research literature on the application of AI and related technologies in trauma treatment was reviewed and summarized in terms of prehospital assistance, in-hospital emergency care, and post-traumatic stress disorder risk regression prediction, meanwhile, the development trend of AI technology in trauma treatment were outlooked.
RESULTS:
The AI technology can rapidly analyze and manage large amount of clinical data to help doctors identify patients' situation of trauma and predict the risk of possible complications more accurately. The application of AI technology in surgical assistance and robotic operations can achieve precise surgical plan and treatment, reduce surgical risks, and shorten the operation time, so as to improve the efficiency and long-term effectiveness of the trauma treatment.
CONCLUSION
There is a promising future for the application of AI technology in the trauma treatment. However, it is still in the stage of exploration and development, and there are many difficulties of historical data bias, application condition limitations, as well as ethical and moral issues need to be solved.
Humans
;
Artificial Intelligence
;
Operative Time
;
Robotic Surgical Procedures
;
Technology

Result Analysis
Print
Save
E-mail